Alerfast

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alerfast

Property Description
Active ingredient Fexofenadine Hydrochloride
Form Tablet, Oral suspension
Pharmacological class Second-generation Antihistamine
Common purpose Relief of allergy symptoms
Origin Synthetic

Alerfast is a synthetic, single-ingredient medicine designed to manage allergic symptoms. It is a non-sedating compound used for oral administration, formulated to provide relief without causing the drowsiness associated with older medication types.


What Type of Medicine is Alerfast?

Alerfast is medically defined as a second-generation antihistamine, belonging to the therapeutic class of Histamine H1-receptor antagonists. This classification means its primary function is to interfere with the chemical histamine, which is released during an allergic reaction and causes common symptoms. Unlike older, first-generation antihistamines, this drug is engineered to have minimal blood-brain barrier penetration. This focused action in the peripheral body is why Alerfast is characterized as being non-sedating, allowing individuals to achieve sustained symptom control while maintaining mental clarity.


Alerfast Composition and Available Forms

The therapeutic effect of Alerfast is delivered by its sole active component, Fexofenadine Hydrochloride. This substance is a synthetic chemical entity classified as a piperidine derivative. For patient accessibility, the medicine is manufactured in common dosage form(s) for oral intake: the film-coated tablet and the oral suspension. The tablet form contains the active ingredient within an excipient matrix, while the suspension incorporates Fexofenadine Hydrochloride within an aqueous vehicle, a format often designated for younger patient groups. This availability of both solid and liquid presentations reflects a strategic positioning for comprehensive use.


What is the General Therapeutic Purpose of Alerfast?

The general purpose of Alerfast is to provide reliable, sustained relief from the discomfort associated with allergic conditions. It operates by acting on peripheral H1 receptors to interrupt the allergic cascade initiated by histamine release. This mechanism translates directly to the general therapeutic benefit: reducing the severity of sneezing, pruritus (itching), and other common symptoms, offering a typical use scenario for managing seasonal hay fever. Fexofenadine is indicated for the relief of seasonal allergy symptoms. As a long-acting agent, the pharmacological design of Alerfast is focused on offering continuous symptomatic suppression, supporting a consistent quality of life throughout the duration of allergen exposure.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Alerfast?

Possible side effects and safety information

The safety profile of Alerfast (fexofenadine hydrochloride) is documented through regulatory assessments, classifying adverse reactions by frequency and the organ system affected.

Frequency-Classified Adverse Reactions

The most frequently documented effects, classified as Common in regulatory information (affecting up to 1 in 10 people), primarily include headache, drowsiness, dizziness, and nausea. Fatigue is listed as Uncommon.

Adverse reactions reported during post-marketing surveillance, where the Frequency is Not Known, involve several system-organ classes, including:

  • Nervous system disorders: Insomnia, nervousness, sleep disorders, or nightmares (paroniria).
  • Cardiac disorders: Tachycardia (fast heart rate) and palpitations (irregular heartbeat).
  • Immune system disorders: Serious hypersensitivity reactions.

Serious Adverse Reactions and Safety Considerations

Serious adverse reactions, though rare, are documented as manifestations of hypersensitivity, including Systemic Anaphylaxis, Angioedema, dyspnoea (difficulty breathing), and chest tightness. These require immediate attention.

Official regulatory documents note specific population safety considerations:

  • Renal Impairment: Clearance of the active ingredient is reduced, which can increase plasma concentration. Dose adjustment is stated to be necessary in the presence of decreased kidney function.
  • Older Adults: Increased caution is noted, primarily due to the greater likelihood of age-related decreases in renal function that may necessitate dosage adjustment.

Administration is contraindicated in patients with a known hypersensitivity to the active substance or any of its excipients. Additionally, regulatory information notes that co-administration with aluminum and magnesium-containing antacids or certain fruit juices can reduce the absorption of the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below describes the clinical signs and emergency actions officially documented for Fexofenadine Hydrochloride overdosage, strictly based on government regulatory guidance.

Documented Manifestations

Overdose cases have been formally documented to present with specific clinical signs. These commonly include central nervous system effects such as drowsiness, dizziness, and fatigue (or tiredness). Dry mouth is also listed among the documented overdose presentations. Regulatory authorities note that information on severe or life-threatening outcomes remains limited and infrequent; however, the potential for cardiac effects necessitates specific monitoring guidelines.

Mandated Emergency Actions and Management

If an overdose is suspected or a large quantity is ingested, official guidance mandates that individuals seek immediate medical attention and contact the nearest hospital emergency department immediately, or call a Poison Control Center. Management is primarily symptomatic and supportive, as no specific antidote is known. Procedures may include standard measures to remove any unabsorbed drug, such as the administration of activated charcoal. In cases involving the ingestion of large quantities, specific medical procedures like cardiac monitoring and ECG assessment may be required. Special consideration is advised for the elderly and patients with impaired renal function, who are noted to face an increased risk of toxic reactions.

Therapeutic Uses of Alerfast

What Alerfast Treats: Main Uses and Benefits

Alerfast is commonly used across conditions characterized by periods of heightened symptoms to provide supportive relief from the distressing physical discomfort of allergic reactions. It is used to relieve symptoms associated with seasonal allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives).

The medication plays a role in managing symptoms that interfere with daily functioning, including recurrent sneezing, persistent runny nose, itching of the nose and throat, as well as intense pruritus and the appearance of wheals on the skin. It offers symptomatic relief that helps patients cope more steadily with these difficult seasonal or chronic episodes.

In contexts where additional symptomatic support is needed without excessive central nervous system effects, Alerfast is often used during phases when symptoms become more noticeable.

“The medication is intended to support functional stability, as it helps maintain a sense of stability when symptoms are more noticeable during episodes of heightened discomfort.”

Quick Fact: Symptomatic Support for Itching and Sneezing

This medication is relevant for easing symptoms related to inflammatory or irritative states, assisting with managing noticeable manifestations across upper respiratory and dermatological domains, while supporting patients in maintaining routine activities and stability, as it is generally non-sedating.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility Profile

Alerfast (fexofenadine hydrochloride) eligibility is strictly defined by regulatory authorities based on age, physiological status, and underlying health conditions.

Contraindication (Absolute Non-Eligibility):

The medicine is contraindicated for patients with a known history of hypersensitivity to fexofenadine or any of the inactive ingredients in the specific formulation.

Population Group Eligibility Status (Regulatory Wording)
Adults and Adolescents ( ge 12 years) Fully approved for use.
Children (SAR) Approved from 2 years of age and older for Seasonal Allergic Rhinitis (SAR).
Infants Safety and effectiveness are not established for infants under 6 months of age for any indication.
Renal Impairment Use requires a starting dose adjustment/reduction due to altered drug elimination.
Pregnancy Should not be used unless clearly necessary; use is only permitted if the potential benefit justifies the risk.
Lactation Not recommended for use in nursing mothers.

Conditional Use: Patients with hepatic impairment or a history of cardiovascular disease should use the medicine with care as advised in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Alerfast (fexofenadine) has documented interactions with certain medicinal products and over-the-counter preparations, which can affect the concentration of the drug in the bloodstream. The primary interaction pathways involve drug transporters in the digestive tract, as fexofenadine undergoes minimal metabolism in the liver.

Medications that may increase Alerfast concentration

Specific medicines, including the macrolide antibiotic Erythromycin and the azole antifungal agent Ketoconazole, have been shown to increase the plasma levels of fexofenadine by two to three-fold. This effect is likely due to the inhibition of P-glycoprotein, a transporter responsible for limiting fexofenadine absorption from the gut. Caution is advised when these medicines are used concomitantly.

Products that may decrease Alerfast concentration

Antacids that contain aluminum or magnesium hydroxide can significantly reduce the absorption of Alerfast, resulting in lower blood levels and potentially reduced effectiveness. This effect is due to the formation of complexes in the gastrointestinal tract, which prevents the drug from being fully absorbed. To mitigate this interaction, it is advised to separate the administration of Alerfast and these antacids by a minimum of two hours.

Food and Drink Interactions

Consumption of grapefruit, orange, or apple juices should be avoided around the time of taking Alerfast, as these fruit juices can also decrease fexofenadine's bioavailability by inhibiting influx transporters in the intestine.

Mechanism of Action

Selective Blockade of the H1 Receptor

The function of Fexofenadine Hydrochloride involves selective activity within the inflammatory signaling system, engaging the chemical mediator histamine and its specific receptor targets. The mechanism is initiated at the molecular level where the drug acts as a competitive antagonist at the peripheral Histamine H1-receptor . This action suppresses the binding of histamine, a signaling molecule released during allergic responses, thereby preventing receptor activation and the initiation of its downstream cascade. This molecular blockade results in the modulation of processes driven by this distinct signaling pattern.

Modulation of Histamine-Driven Physiological Effects

By interrupting the H1 signaling cascade, the drug modulates two key physiological processes: it limits histamine-induced increased vascular permeability and suppresses the activation of sensory nerve endings. This results in a physiological adjustment that modulates the histamine-driven increase in vascular permeability and sensory nerve activation.

Anatomical Constraint and Peripheral Focus

The molecule is structurally designed to achieve minimal passage across the Blood- Brain Barrier ( BBB). This anatomical constraint ensures that the selective H1 receptor blockade is restricted to peripheral systems, avoiding significant functional engagement of H1 receptors located within the central nervous system ( CNS).

Dosage and Administration Information

The usage of Alerfast (Fexofenadine Hydrochloride) is based on parameters for consistent and proper administration. This medication is intended for oral intake and is available as film-coated tablets in strengths including 30 mg, 60 mg, 120 mg, and 180 mg, as well as an oral suspension. The frequency pattern for use is either once or twice daily, depending on the dose and the specific condition being managed.

Population Standard Dosing Regimen Dose Adjustment for Renal Impairment
Adults & Adolescents (≥ 12 years) 180 mg once daily or 60 mg twice daily 60 mg once daily
Children (6 to 11 years) 30 mg twice daily 30 mg once daily

Tablets are swallowed whole with water. An important administration constraint is to avoid taking the medicine with fruit juices (such as grapefruit, orange, or apple) as these may reduce the absorption of the active ingredient. For the oral suspension, the container is shaken well before measuring. If the use of antacids containing aluminum or magnesium is necessary, a gap of approximately two hours is required before or after administration.

If a dose is missed, it is skipped if it is close to the time for the next scheduled dose, and the regular schedule resumed. A double dose is not taken to correct the omission.

Recent Clinical Evidence

Alerfast: Recent Clinical Evidence


1. Evidence for Use in Seasonal Allergic Rhinitis (SAR)

Research exploring symptom patterns in seasonal allergic rhinitis (commonly known as hay fever) has primarily involved short-term, randomized controlled trials (RCTs). These studies compared the experience of individuals taking Alerfast to those receiving an inactive placebo. Researchers examined patient-reported outcomes describing perceived discomfort by measuring changes in overall allergy symptom severity, including sneezing, runny nose, and ocular (eye) outcomes linked to irritative states. Regulatory evidence is largely based on findings that describe patterns observed in these studies, which monitored how symptom scores evolved across different study groups over the typical trial duration of two to four weeks.

What remains uncertain is the full picture of long-term outcomes regarding the continued pattern of symptoms over multiple seasons, as the pivotal efficacy trials primarily focused on short-term changes. Data for the youngest pediatric groups (under 6 years) are still emerging, often relying on extrapolation from data collected from older populations.


2. Evidence for Use in Chronic Idiopathic Urticaria (CIU)

Studies focused on Chronic Idiopathic Urticaria (CIU) have mainly involved short-term, placebo-controlled RCTs of adults and adolescents. The main outcomes research examined were changes in the severity of pruritus (itching) and the number of wheals (hives), which were combined into a Total Symptom Score. The evidence, characterized as High-quality based on study design, is based on multiple RCTs that consistently monitored symptom changes across the study groups. Limited information for long-term outcomes is available, and findings were mixed in research that examined very high doses in individuals with CIU who did not respond to standard dosing.


3. Research Focus on Peripheral and Cognitive Function

Specialized research has explored the low central nervous system effects of Alerfast. Studies monitored outcomes reflecting daily functioning by using objective psychomotor function tests (e.g., reaction time and attention scores) in both healthy volunteers and patients with allergic diseases. Data show patterns related to a low reported frequency of drowsiness in these studies. The level of scientific certainty is considered high for findings related to the peripheral profile based on these specialized psychomotor testing results.

Key Studies & References

  1. Public Assessment Report Scientific discussion Nefoxef film-coated tablets 120 mg and 180 mg Fexofenadine hydrochloride (EMA/National Agency Review)

Frequently Asked Questions (FAQ)

Common questions about Alerfast (FAQ)


Q: How long does it typically take before Alerfast starts working?

Regulatory studies and clinical data indicate that an antihistamine effect may be observed relatively quickly, often within 60 minutes after taking a single dose. The maximum reduction in allergy symptoms is generally noted to occur approximately two to three hours after administration.


Q: How long do the effects of Alerfast usually last?

Official pharmacological studies show that the medication is designed to be long-acting. The beneficial effect on allergy symptoms following a standard dose is observed to be sustained throughout the typical 12-hour dosing interval.


Q: Can Alerfast affect my ability to drive or operate machinery?

While Alerfast is officially characterized as a non-drowsy antihistamine, official regulatory guidance advises that individuals should exercise caution when driving or operating complex machinery until they know how the medicine affects them.


Q: Is Alerfast safe for long-term use?

Clinical studies supporting the drug's use often involve treatment durations of two to four weeks. Regulatory data reports that there was no evidence of tolerance (a diminished effect over time) to the antihistamine's effects after 28 days of dosing. Determining the appropriateness of continuous, multi-season use is a matter for individual consultation.


Q: Is it possible to develop a tolerance to Alerfast over time?

Official clinical studies have specifically looked into whether the drug's effectiveness decreases over time, a concept known as tachyphylaxis. Studies conducted over periods up to 28 days have shown no evidence of tolerance developing to the antihistamine effects in the participants examined.


Q: What happens if I accidentally take two doses of Alerfast close together?

Regulatory documents describe that symptoms seen after taking very large, accidental doses are generally consistent with the known side-effect profile. These may include signs such as dizziness, drowsiness, and dry mouth. Official guidance for patients is to seek medical advice for any suspected overdose.


Q: Is Alerfast a common over-the-counter medicine?

Yes, Alerfast (Fexofenadine) has transitioned from prescription-only status to become commonly available as an over-the-counter (OTC) medicine in many major regions. This status is generally for specific dosage strengths and pack sizes.


Q: What is the difference between Alerfast and a similar-sounding medicine called 'Alerfast-D'?

Alerfast is a single-ingredient product containing Fexofenadine. The 'Alerfast-D' formulation is a combination product that contains two different active ingredients: Fexofenadine, plus an additional component, typically a decongestant (like Pseudoephedrine), for managing nasal congestion.


Q: How is Alerfast different from other medicines that treat the same things?

Official classification defines Alerfast as a second-generation antihistamine. A key distinction noted in official pharmacological profiles is its design for minimal penetration of the central nervous system (CNS), which is intended to reduce the risk of drowsiness compared to older drug classes.


Q: Why do some people say Alerfast works better than other options?

Official documentation relies on data from short-term controlled studies that demonstrate Alerfast's effectiveness in reducing total allergy symptom scores. Additionally, specialized research supports its primary activity being focused on the peripheral body with a low reported frequency of drowsiness, which is a key distinction reported in regulatory texts.


Q: Is it normal to feel a bit restless after taking Alerfast?

While restlessness itself is not listed as a common side effect, official post-marketing surveillance reports have included less frequent adverse reactions in the nervous system. These include reports of nervousness and insomnia (trouble falling or staying asleep).


Q: Can Alerfast be crushed or broken if I have trouble swallowing pills?

Official administration instructions for the standard film-coated tablet formulation explicitly state that the tablets should be swallowed whole with water. Regulatory labeling does not advise breaking, crushing, or chewing the pill.


Q: Can Alerfast be taken at any time of day?

For formulations taken once daily, the medication may generally be taken at any time of day, according to common guidance. Some regulatory labels may, however, advise taking certain higher doses before a meal.


Q: Does Alerfast interact with common herbal supplements?

Regulatory-adjacent guidance notes that certain supplements, such as St. John's wort, have been shown to interfere with the body's uptake of Fexofenadine. Official labeling advises discussing all concurrent medications and supplements with a healthcare provider.


Q: Does Alerfast interact with alcohol?

Official regulatory documents do not state that alcohol consumption affects the concentration of Fexofenadine in the body. However, the risk of common side effects like drowsiness or dizziness may be increased when consuming alcohol while taking the medication.


Q: Can Alerfast be used during specific seasons, or is it for year-round use?

The drug is officially approved for managing symptoms of Seasonal Allergic Rhinitis (seasonal hay fever) and Chronic Idiopathic Urticaria (persistent hives). Therefore, its use is guided by the duration and recurrence of these specific, officially approved conditions.


Q: Is Alerfast safe during pregnancy or breastfeeding, based on official sources?

Official regulatory guidance advises that the drug should not be used during pregnancy unless clearly necessary and the potential benefit is assessed to justify any potential risk. Use in nursing mothers is generally not recommended based on official documents.


Q: Does Alerfast carry any specific warnings for people with glaucoma?

Official documents for Alerfast, as a second-generation antihistamine, do not list specific glaucoma warnings. This class of medication is generally preferred over older antihistamines because it has minimal anticholinergic properties, which are the compounds that may potentially worsen glaucoma.


Q: What evidence exists for using Alerfast beyond its main approved use?

The evidence cited in regulatory documents is focused exclusively on the efficacy of Alerfast for the approved indications, which are Seasonal Allergic Rhinitis (SAR) and Chronic Idiopathic Urticaria (CIU). Official labeling does not describe or support the use of the medicine for unapproved conditions.


Q: What is the classification of Alerfast?

Alerfast is formally classified as a second-generation antihistamine, belonging to the larger therapeutic class of Histamine H1-receptor antagonists. This classification is based on its specific function of blocking the action of histamine in the peripheral body.

How should Alerfast be stored and disposed of?

How to Store and Dispose of Alerfast

The storage and disposal of Alerfast (fexofenadine hydrochloride) must adhere strictly to official regulatory requirements to maintain product stability.

Storage Requirements

Temperature and Protection: The medication must be stored at controlled room temperature, ideally between 20°C and 25°C (68°F and 77°F). It is mandatory to keep the product from freezing and to protect it from excessive moisture. Tablets should be stored in a closed container.

Child Safety: As an official safety requirement, the medicine must be kept out of the reach of children.

Disposal

Unused Product: Do not keep medicine that is outdated or no longer needed. Official guidance instructs that patients should ask a healthcare professional how to properly dispose of any unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alerfast found in:

A-Z Index: